Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Pharmaceuticals & Biotechnology | Small Cap
Health Score : 7.46Aarti Pharmalabs Ltd demonstrates a mixed financial performance. The company shows excellent solvency, growth, coverage, and profitability, indicating a strong ability to meet long-term obligations, expand its operations, cover its financial obligations, and generate profits. Its financial ratios are also strong, driven by high adjusted and cash earnings per share and book value. However, the company's liquidity and efficiency ratios suggest some challenges in managing short-term obligations and utilizing assets effectively. While revenue and profit growth are robust, the company needs to focus on improving its working capital management and asset turnover to achieve a more balanced financial profile. Capital expenditure is a concern. Overall, Aarti Pharmalabs exhibits solid financial health with potential for further improvement in specific areas.
Health Score : 7.46Aarti Pharmalabs Ltd demonstrates a mixed financial performance. The company shows excellent solvency, growth, coverage, and profitability, indicating a strong ability to meet long-term obligations, expand its operations, cover its financial obligations, and generate profits. Its financial ratios are also strong, driven by high adjusted and cash earnings per share and book value. However, the company's liquidity and efficiency ratios suggest some challenges in managing short-term obligations and utilizing assets effectively. While revenue and profit growth are robust, the company needs to focus on improving its working capital management and asset turnover to achieve a more balanced financial profile. Capital expenditure is a concern. Overall, Aarti Pharmalabs exhibits solid financial health with potential for further improvement in specific areas.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
44.51
Industry Median
30.91
Small Cap Median
28.64
P/E RATIO
44.90
P/B RATIO
3.70
Industry Median
3.69
Small Cap Median
3.11
P/S RATIO
4.11
Industry Median
3.74
Small Cap Median
3.02
Others
PEG RATIO
0.00
EV/EBITDA RATIO
20.12
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹865.2 as on Sep 1, 2026.
Growth Score : 10.00The company exhibits excellent growth across various metrics, including revenue, operating profit, EPS, assets, and net income. This indicates a strong upward trajectory and effective growth strategies. The company's consistent growth positions it well for future success and market leadership.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue Growth Rate | 62.08 | -4.73 | 14.14 | -14 |
| Operating Profit Growth Rate | 65.22 | 12.87 | 20.21 | -20.47 |
| Earnings Per Share (EPS) Growth | 12.08 | 25.57 | -35.87 | |
| Asset Growth Rate | 10 | 15.06 | 12.55 | 19.82 |
| Net Income Growth Rate | 58.2 | 12.44 | 25.35 | -35.66 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | FDC Ltd | 7.64 | 19.29 | Neutral | 346.00 | 17.56 | 281.00 |
| 2 | Supriya Lifescience Ltd | 7.46 | 30.91 | Overvalued | 294.00 | 25.98 | 209.00 |
| 3 | Aarti Pharmalabs Ltd | 7.46 | 44.90 | Neutral | 369.00 | 19.43 | 175.00 |
| 4 | Innova Captab Ltd | 7.36 | 43.37 | Overvalued | 243.00 | 14.63 | 141.00 |
| 5 | Akums Drugs & Pharmaceuticals Ltd | 7.28 | 48.06 | Overvalued | 522.00 | 7.09 | 256.00 |
| 6 | Marksans Pharma Ltd | 7.24 | 34.97 | Neutral | 601.00 | 6.64 | 420.00 |
| 7 | Aarti Drugs Ltd | 7.20 | 20.00 | Undervalued | 309.00 | 18.54 | 195.00 |
| 8 | Hikal Ltd | 7.13 | -50.14 | Neutral | 220.00 | -3.95 | -49.00 |
| 9 | RPG Life Sciences Ltd | 7.12 | 37.20 | Neutral | 147.00 | 69.64 | 115.00 |
| 10 | Alembic Ltd | 7.06 | 8.00 | Undervalued | 90.00 | 4.85 | 317.00 |
| 11 | SMS Pharmaceuticals Ltd | 5.94 | 33.82 | Neutral | 171.00 | 9.35 | 102.00 |
| 12 | Shilpa Medicare Ltd | 5.94 | 71.52 | Highly Overvalued | 435.00 | 6.80 | 243.00 |
| 13 | Strides Pharma Science Ltd | 5.55 | 16.97 | Undervalued | 925.00 | 19.92 | 575.00 |
| 14 | Jeena Sikho Lifecare Ltd | 5.52 | 28.20 | Neutral | 349.00 | 17.87 | 222.00 |
| 15 | Gufic BioSciences Ltd | 5.49 | 65.79 | Neutral | 151.00 | 6.30 | 64.00 |
| 16 | Dishman Carbogen Amcis Ltd | 5.38 | 29.23 | Neutral | 566.00 | -2.45 | 97.00 |
| 17 | IOL Chemicals & Pharmaceuticals Ltd | 5.31 | 40.61 | Neutral | 269.00 | 4.69 | 138.00 |
| 18 | Orchid Pharma Ltd | 4.85 | 234.05 | Neutral | 41.00 | 8.91 | 21.00 |
| 19 | Sequent Scientific Ltd | 4.61 | 301.49 | Overvalued | 162.00 | 1.74 | 32.00 |
| 20 | Sun Pharma Advanced Research Company Ltd | 4.35 | 4.12 | Neutral | 1599.00 | 47.83 | 1553.00 |
| 21 | Zota Health Care Ltd | 3.97 | -48.15 | Neutral | 19.00 | 8.06 | -74.00 |
| 22 | Procter & Gamble Health Ltd | 3.45 | 29.33 | Neutral | 466.00 | 215.00 | 357.00 |
| 23 | Sanofi India Ltd | 3.45 | 17.56 | Neutral | 491.00 | 134.52 | 413.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Aarti Pharmalabs Ltd is a leading Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and providing Contract Development and Manufacturing Organisation (CDMO) services. Demerged from Aarti Industries, it focuses on delivering high-quality and complex chemistries for regulated markets, leveraging its strong R&D capabilities.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Aarti Pharmalabs Ltd's P/E ratio (TTM) is 44.51, compared to the industry median of 30.91 and large cap median of 28.64.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Aarti Pharmalabs Ltd's P/B ratio is 3.70, compared to the industry median of 3.69 and large cap median of 3.11.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Aarti Pharmalabs Ltd's P/S ratio is 4.11, compared to the industry median of 3.74 and large cap median of 3.02.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Aarti Pharmalabs Ltd's PEG ratio is 1.28.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Aarti Pharmalabs Ltd's EV/EBITDA ratio is 20.12.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Aarti Pharmalabs Ltd's ROE is 8.24%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Aarti Pharmalabs Ltd's ROA is 10.60%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Aarti Pharmalabs Ltd's ROCE is 11%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Aarti Pharmalabs Ltd's operating margin is 20.29%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Aarti Pharmalabs Ltd's net margin is 9.62%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Aarti Pharmalabs Ltd's current ratio is 1.32.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Aarti Pharmalabs Ltd's debt-to-equity ratio is 0.12.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Aarti Pharmalabs Ltd's interest coverage ratio is 5.96.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Aarti Pharmalabs Ltd's DPS is ₹3.47.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Aarti Pharmalabs Ltd's EPS is -35.87.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹865.20. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 2019 (as Aarti Organics Limited)
Headquarters: Mumbai, Maharashtra
Core Offerings: Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Contract Development and Manufacturing Organisation (CDMO)
Stock Listing: NSE (AARTIPHARM), BSE (543748)
Promoter: Gogri Family / Aarti Group
Aarti Pharmalabs Limited was incorporated on April 26, 2019, as Aarti Organics Limited, initially operating as a subsidiary of Aarti Industries Limited, focusing on pharmaceutical intermediates and APIs. The company underwent a strategic demerger from Aarti Industries Limited to create a focused pharmaceutical entity. Effective January 3, 2023, the company was officially renamed Aarti Pharmalabs Limited and was subsequently listed as an independent company on the Indian stock exchanges, specializing in the pharmaceutical sector.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Active Pharmaceutical Ingredients & Intermediates | 100% | Integrated operations |
Active Pharmaceutical Ingredients (APIs): Manufactures a diverse portfolio of APIs for various therapeutic areas, serving both innovator and generic pharmaceutical companies globally. Capabilities include complex multi-step synthesis and high-potency API manufacturing.
Pharmaceutical Intermediates: Produces key advanced intermediates critical for the synthesis of complex pharmaceutical molecules.
Contract Development and Manufacturing Organisation (CDMO): Offers custom synthesis and contract manufacturing services for pharmaceutical customers, leveraging its R&D and manufacturing expertise for new drug development and commercial production.
Mr. Rajendra V. Gogri: Chairman & Whole-time Director. With over three decades of experience, he has been instrumental in the growth of the Aarti Group, providing strategic vision and leadership. Mr. Rashvesh R. Gogri: Managing Director & CEO. Holds a Master's degree in Chemical Engineering and brings significant experience in the chemical and pharmaceutical industries, driving the company's operational excellence and strategic expansion.
No major subsidiaries reported.
Significant demerger from Aarti Industries Limited, effective January 2023, resulting in its independent listing on stock exchanges.
The Aarti Pharmalabs Ltd share price today is ₹865.20 on NSE (AARTIPHARM), as of 26 Sept 2026.
As of 25 Sept 2026, Aarti Pharmalabs Ltd share price is ₹865.20, with previous close ₹865.20. Today's range is ₹865.20 to ₹865.20. The 52-week range is ₹585 to ₹962.
As of today, Aarti Pharmalabs Ltd's market cap is ₹7,483.98 crore (Mid Cap).
Aarti Pharmalabs Ltd's current P/E ratio is 44.51, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 34.10.
Aarti Pharmalabs Ltd's current P/B ratio is 3.70.
Aarti Pharmalabs Ltd's current dividend yield is 0.40%. Last dividend of ₹2.00 per share was declared on 17-May-2024.
Aarti Pharmalabs Ltd's EPS (TTM) is ₹-35.87.
Aarti Pharmalabs Ltd is a leading Indian pharmaceutical company specializing in the manufacturing of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and providing Contract Development and Manufacturing Organisation (CDMO) services. Demerged from Aarti Industries, it focuses on delivering high-quality and complex chemistries for regulated markets, leveraging its strong R&D capabilities.
Aarti Pharmalabs Ltd is promoted by Gogri Family / Aarti Group, holding 43.08% as of 25 Sept 2026.
Aarti Pharmalabs Ltd is listed on NSE (AARTIPHARM) and BSE (543748). Its next quarterly results are expected on August 2024 (Q1 FY25).
Capital Expenditures (CapEx)
Financial Performance & Growth
